Background: Apremilast, a phosphodiesterase-4 inhibitor with anti-inflammatory activity, has potential for wound management; however, poor aqueous solubility and limited topical retention may reduce its effectiveness. Nanosponge-based gels may enhance local retention and sustained drug release. Methodology: Nine nanosponge gel formulations (NSG1–NSG9) were prepared using varying concentrations of Carbopol 934 and propylene glycol. Formulations were evaluated for homogeneity, pH, viscosity, spreadability, extrudability, and drug content. In vitro release was assessed for 24 h using a Franz diffusion cell. The optimized formulation was evaluated for dermal irritation and wound-healing efficacy in Wistar rats using an excision wound model. Histopathological examination and a three-month stability study were also performed. Results and Discussion: NSG7 showed optimal characteristics, with pH 5.92 ± 0.04, viscosity 9,850 ± 145 cP, spreadability 4.8 ± 0.12 g·cm/s, extrudability 440 ± 8 g, and drug content 99.2 ± 0.4%. Drug release reached 82.19 ± 6.80% at 12 h and 94.97 ± 4.91% at 24 h. NSG7 was non-irritant and enhanced wound contraction, epithelialization, collagen deposition, and tissue remodeling compared with untreated and conventional apremilast gel groups. However, the absence of a drug-free Carbopol 934 vehicle control prevented separation of vehicle- related effects from those of the drug-loaded nanosponge system. Conclusion: NSG7 demonstrated favorable sustained drug release, dermal safety, and promising wound-healing activity. The observed in vivo benefits may reflect combined effects of apremilast- loaded nanosponges. Further studies incorporating a vehicle control and extended preclinical and clinical evaluation are warranted.
Copyrights © 2026